A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor
To the Editor: Topical corticosteroids are among the cornerstone treatments of atopic dermatitis (AD); however, prolonged use is associated with skin atrophy, hypopigmentation, and telangiectasia.1 Nonsteroidal alternatives include topical calcineurin inhibitors such as pimecrolimus and tacrolimus and the phosphodiesterase 4 inhibitor crisaborole, which have application site pain as a side effect. The mechanism by which crisaborole induces pain is unknown.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Christine Pao-Ling Lin, Samantha Gordon, Min Ji Her, David Rosmarin Tags: Research letter Source Type: research
More News: Academies | Corticosteroid Therapy | Dermatitis | Dermatology | Elidel | Hypopigmentation | Pain | Prograf | Skin | Study | Tacrolimus